NYT story - March 12, 2013 - Smallpox -- US buy drug
Wary of Attack With Smallpox, U.S. Buys Up a Costly DrugBy DONALD G. McNEIL Jr.
via New York Times --- March 12, 2013
Journalists have a tendancy to express matters sensationally.
So here the are conflicting views. as to dose price of ST-246 reasonableness and supply level needed.
These negative claims in my view were confusions expressed as knowledge. Be that as it may , these claims serve the journalist.
I cite below some excerpts of information that I believe to be the most relvant to SIGA in the years ahead.
======Robin Robinson, director of the Biomedical Advanced Research and Development Authority, part of the Department of Health and Human Services, the overseer of the contract for the drug, Arestvyr, defended the size of the order and the price paid. He said that two million doses was the amount analysts predicted would be needed to contain a smallpox outbreak in a large city and that the whole country would require 12 million, along with vaccines
The price, he said, was arrived at through federal purchasing guidelines and was “fair and reasonable” compared with the price of other commercial antiviral drugs, which he said ranged from $108 to $7,364.
=======Eric Rose----Asked about the size of the purchase, he compared it with a flu drug. “There are 80 million courses of Tamiflu in the strategic national stockpile,” he said. “Smallpox is just as contagious and has 30 times the mortality. By measures like that, I’d say 2 million is on the low end.”
=======Dr. Isaac B. Weisfuse, who was formerly head of pandemic planning for the New York City health department and is now Siga’s medical policy director, said that plans calling for tens of million Americans to be vaccinated within days of a major smallpox outbreak were unrealistic and that Arestvyr could save lives